Semen News and Research

RSS

Semen is an organic fluid, also known as seminal fluid, that usually contains spermatozoa. It is secreted by the gonads (sexual glands) and other sexual organs of male or hermaphroditic animals and can fertilize female ova. The process of discharge is called ejaculation.

Prostatic artery embolization comparable to transurethral resection

A new interventional radiology treatment that blocks blood supply to men's enlarged prostate glands shows comparable clinical results to transurethral resection of the prostate (or TURP), considered the gold standard (or most common) treatment. However, this minimally invasive treatment-prostatic artery embolization-has none of the risks associated with TURP, such as sexual dysfunction, urinary incontinence, blood loss and retrograde ejaculation, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago.

30 Mar 2011

Organochloride pesticide exposure can alter semen quality in young people

Two in 10 young people in South East Spain have poor sperm density, which involves requiring more time to accomplish fertilization. The most common means of exposure to pesticides is food and other household products.

23 Mar 2011

Nationwide observance raises awareness about HIV/AIDS spread in women

National Women and Girls AIDS Awareness Day, a nationwide observance that raises awareness and promotes action in the fight against HIV/AIDS, took place on March 10.

17 Mar 2011

TESE offers fertility to male cancer survivors

An intricate procedure that finds and carefully removes individual sperm from testicular tissue has made fathers of men who were once considered sterile due to prior cancer treatment, say researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center who pioneered the technique.

16 Mar 2011

TESE surgical technique can help men with childhood cancer experience parenthood

A new study has shown that a surgical technique called microdissection testicular sperm extraction can effectively locate and extract viable sperm in more than one-third of adult male childhood cancer survivors who were previously considered sterile due to prior chemotherapy treatment.

15 Mar 2011

5a-reductase inhibitors for male health problems can affect sexual health

A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.

7 Mar 2011

New study: Significant deterioration in semen quality during last 10 years in Finland

A new study published in the International Journal of Andrology reveals that semen quality has significantly deteriorated during the last ten years in Finland, a country that previously was a region with high sperm counts.

3 Mar 2011

Microbix first quarter revenues decrease 34% to $812,694

Microbix Biosystems Inc., a biotechnology company commercializing novel technologies for influenza vaccine manufacturing and livestock semen sexing, in addition to a core business of virology products, today reported financial results for the first quarter of fiscal 2011. For the quarter ended December 31, 2010, Microbix reported revenues of $812,694, a 34% decrease from $1,226,538 for the same period in 2009.

14 Feb 2011

Gene-transfer system may control mosquito-borne diseases without pesticides

Scientists have modeled a system that may be used to control mosquitoes and the diseases they transmit, without the use of pesticides. In the proposed system, mosquitoes are engineered to carry two genes. The first gene causes males to transmit a toxin to females through their semen. The second gene, when expressed in females, makes them immune to this toxin.

14 Feb 2011

Semen allergy to one's own

According to a study from Dutch researchers, some men are allergic to their own semen, developing a mysterious flu-like illness after they have an ejaculation. The condition, known as post-orgasmic illness syndrome or POIS, has been documented since 2002. It manifests as feverishness, runny nose, extreme fatigue and burning eyes, which can last for up to a week.

20 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

Repros receives IRB approval for Androxal Phase IIb study in secondary hypogonadism

Repros Therapeutics Inc. today reported it has received Institutional Review Board (IRB) approval to commence the Phase IIb study of Androxal® in men with secondary hypogonadism. The Company has submitted the protocol for FDA comment and plans to begin enrolling subjects in January. Depending on the rate of subject enrollment, Repros hopes to have the study completed before the end of 2011.

3 Jan 2011

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Celgene International Sàrl today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52nd Annual Meeting of the American Society of Hematology comparing REVLIMID® (lenalidomide) plus low-dose dexamethasone (Rd) to lenalidomide plus high-dose dexamethasone (RD) in both younger and older newly-diagnosed multiple myeloma patients (NDMM).

7 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck today reported initial results from the Phase III study investigating the efficacy and safety of a treatment regimen including ISENTRESS® (raltegravir) Tablets once daily in treatment-naïve adult patients infected with HIV-1. ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve and treatment-experienced adults.

29 Nov 2010

ESF report: Reduced male fertility may contribute to low birth rates

Reduced male fertility may be making it even harder for couples to conceive and be contributing to low birth rates in many countries, reveals a new European Science Foundation (ESF) report launching today at the IPSEN meeting in Paris.

28 Nov 2010

Food allergies may lead to 'kissing' allergies

Even brushing your teeth or waiting hours after eating may not prevent some partners of people with food and medicine allergies from triggering an allergic reaction through a kiss, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Nov.11-16.

17 Nov 2010

Using mild painkillers during pregnancy can increase risk of male reproductive disorders

New evidence has emerged that the use of mild painkillers such as paracetamol, aspirin and ibuprofen, may be part of the reason for the increase in male reproductive disorders in recent decades.

10 Nov 2010

Gene fusion prostate cancers susceptible to secondary mutations

Scientists at Weill Cornell Medical College have taken an important step toward a better understanding of prostate cancer by uncovering evidence that it is not one disease, as previously believed, but rather several factors which can be measured and, in the future, destroyed by targeted therapy.

4 Nov 2010